Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2023 | Selecting conditioning regimens for patients with myelofibrosis undergoing alloSCT

Wael Saber • 21 Oct 2023
COSTEM 2023
Myelofibrosis Myeloproliferative Neoplasms Busulfan Fludarabine

Wael Saber, MD, MS, Froedtert & Medical College of Wisconsin, Milwaukee, WI, discusses a study analyzing the choice of conditioning regimen for patients with myelofibrosis (MF) undergoing allogeneic stem cell transplantation (alloSCT), and which are optimal. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Wael Saber

1:05
Using whole genome sequencing to identify novel predictors for SCT in patients with MDS
Wael Saber • 21 Oct 2023
1:40
Unrelated younger donors vs older sibling donors when transplanting patients with MDS & AML
Wael Saber • 21 Oct 2023
1:40
How donor age impacts outcomes in patients with AML undergoing alloSCT
Wael Saber • 21 Oct 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals